IP Library Granted Patent US 7,083,981
Granted Patent B2
US 7,083,981 · App. 11/186,497 · Granted Aug 1, 2006

Method and means for producing high titer, safe, recombinant lentivirus vectors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,083,981
App. No.
11/186,497
Granted
Aug 1, 2006
Kind
B2
Abstract

Lentiviral vectors modified at the 5′ LTR or both the 5′ and 3′ LTR's are useful in the production of recombinant lentivirus vectors. Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production.

Claims (21)

1. A lentivirus transfer vector comprising a 5′ LTR and a 3′ LTR, each of which contains a U3 region and an endogenous R region, wherein a part or all of a regulatory element of the U3 region of the 5′ LTR is replaced by another regulatory element, operable in a mammalian cell, which is not endogenous to said lentivirus, and wherein one or more nucleotide bases of the U3 region of the 3′ LTR are deleted.

2. The vector of claim 1 , wherein said regulatory element not endogenous to said lentivirus is a cytomegalovirus enhancer, promoter or enhancer/promoter.

3. The vector of claim 1 , wherein said regulatory element not endogenous to said lentivirus is a Rous sarcoma virus enhancer, promoter or enhancer/promoter.

4. The transfer vector of claim 1 , wherein said U3 region deleted is all of said U3 region except for a 5′ terminal dinucleotide and an att sequence.

5. The transfer vector of claim 1 , wherein said U3 region deleted includes a TATA box sequence.

6. The transfer vector of claim 1 , wherein said vector carries an expressed heterologous gene.

7. The transfer vector of claim 1 , wherein said lentivirus is human immunodeficiency virus (HIV).

8. The transfer vector of claim 7 , wherein said HIV is HIV-1.

9. A lentivirus packaging plasmid lacking sequences upstream from gag endogenous to said lentivirus, lacking sequences downstream from env endogenous to said lentivirus, and lacking a functional tat gene.

10. The packaging plasmid of claim 9 , wherein said plasmid carries an expressed gag, an expressed pol or expressed gag and pol genes.

11. The packaging plasmid of claim 9 , wherein said lentivirus is human immunodeficiency virus (HIV).

12. A method for producing a recombinant lentivirus vector comprising:

a) transforming a cell with:

i) at least one lentivirus packaging plasmid of claim 9 ; and

ii) an expression plasmid not endogenous to said lentivirus which carries an env gene not endogenous to said lentivirus;

to yield a packaging cell;

b) multiply transforming said packaging cell with a lentivirus transfer vector which comprises a heterologous gene to yield a producer cell;

c) culturing said producer cell in a medium; and

d) separating said producer cell from said medium to recover said recombinant lentivirus vector from said medium.

13. The packaging plasmid of claim 11 , wherein said HIV is HIV-1.

14. The method of claim 12 , wherein said lentivirus transfer vector comprises a 5′ LTR and a 3′ LTR, each of which contains U3 region and an endogenous R region, wherein a part or all of a regulatory element of the U3 region of the 5′ LTR is replaced by another regulatory element, operable in a mammalian cell, which is nor endogenous to said lentivirus, wherein one or more nucleotide bases of the U3 region of the 3′ LTR are deleted.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2014
From: GBP IP, LLC
To: MILTENYI BIOTEC TECHNOLOGY, INC
Reel/Frame 033666/0185 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2008
From: CELL GENESYS, INC.
To: GBP IP, LLC
Reel/Frame 020666/0224 →